Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial
Urology Journal,
Vol. 18 No. 05 (2021),
7 November 2021
,
Page 543-548
https://doi.org/10.22037/uj.v18i05.6274
Abstract
Purpose: SNRIs (serotonin and norepinephrine reuptake inhibitors) like duloxetine are known to have role in the treatment of anxiety disorder and stress urinary incontinence. According to the correlation of anxiety disorder and overactive bladder, this study aimed to evaluate the clinical efficacy and complications of duloxetine (SNRI) as a medication in the treatment of overactive bladder in the female patients. We were interested to know the probable therapeutic effect and side effects of duloxetine in overactive bladder.
Methods and Materials: In this single-blinded interventional randomized clinical trial, 60 female patients with idiopathic overactive bladder (hyperreflexia) referred to the urology clinic, were divided into two groups as pilots. The first group were treated by 10mg/daily solifenacin and the second group received 20mg/daily duloxetine. The patients were evaluated by the ICIQ-OAB Questionnaire before and after one-month follow-up period. The intervention primary outcomes were evaluated by the patient’s presentation of the frequency, nocturia, urgency, urge urinary incontinence and the drugs side effects as secondary outcomes were checked.
Results: Sixty women with confirmed overactive bladder disease were evaluated. Solifenacin and duloxetine had the same effect on the treatment of overactive bladder (p value=0.148). The clinical symptoms were obviously relieved in both groups after treatment. Side effects were insignificantly more common in the solifenacin group (p value>0.05). However, the different frequency of blurred vision in the two groups was statistically significant (p value=0.04). The most common complication in solifenacin and duloxetine group was anxiety.
Conclusion: The results showed that solifenacin and duloxetine improved overactive bladder symptoms. According to this evaluation, duloxetine can be a suitable alternative option for overactive bladder treatment, due to the acceptable therapeutic effect and side effects.
- Solifenacin
- Duloxetine
- Overactive bladder
- Stress urinary incontinence
How to Cite
References
Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7-12; discussion
Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. International journal of fertility and women's medicine. 1999;44(2):56-66.
Demaagd GA, Davenport TC. Management of urinary incontinence. P T. 2012;37(6):345-61H.
Gibbs CF, Johnson TM, 2nd, Ouslander JG. Office management of geriatric urinary incontinence. The American journal of medicine. 2007;120(3):211-20.
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. The Journal of urology. 2012;188(6 Suppl):2455-63.
Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs & aging. 1995;6(3):243-62.
Hebjørn S, Andersen JT, Walter S, Mouritzen Dam A. Detrusor Hyperreflexia. Scandinavian Journal of Urology and Nephrology. 1976;10(2):103-9.
Liu HT, Jiang YH, Kuo HC. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. PloS one. 2013;8(10):e76706.
Torimoto K, Matsumoto Y, Gotoh D, Morizawa Y, Miyake M, Samma S, et al. Overactive bladder induces transient hypertension. BMC Res Notes. 2018;11(1):196-.
Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. European urology. 2014;65(1):79-95.
Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourology and Urodynamics. 2013;32(3):230-7.
Milsom I, Stewart W, Thüroff J. The prevalence of overactive bladder. The American journal of managed care. 2000;6(11 Suppl):S565-73.
Robinson D, Cardozo L, Milsom I, Pons ME, Kirby M, Koelbl H, et al. Oestrogens and overactive bladder. Neurourology and Urodynamics. 2014;33(7):1086-91.
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World journal of urology. 2003;20(6):327-36.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. The Journal of urology. 2015;193(5):1572-80.
Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. The American journal of managed care. 2000;6(11 Suppl):S580-90.
Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. The American journal of medicine. 1996;101(3):281-90.
Bear M, Dwyer JW, Benveneste D, Jett K, Dougherty M. Home-based management of urinary incontinence: a pilot study with both frail and independent elders. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society. 1997;24(3):163-71.
Ouslander JG. Management of overactive bladder. The New England journal of medicine. 2004;350(8):786-99.
Ahn K-S, Hong H-P, Kweon H-J, Ahn A-L, Oh E-J, Choi J-K, et al. Correlation between Overactive Bladder Syndrome and Obsessive Compulsive Disorder in Women. Korean J Fam Med. 2016;37(1):25-30.
Arnold J, McLeod N, Thani-Gasalam R, Rashid P. Overactive bladder syndrome - management and treatment options. Australian family physician. 2012;41(11):878-83.
Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. British journal of clinical pharmacology. 2015;80(2):209-20.
Babu R, Vaidyanathan S, Sankaranarayan A, Indudhara R. Effect of intravesical instillation of varying doses of verapamil (20 mg, 40 mg, 80 mg) upon urinary bladder function in chronic traumatic paraplegics with overactive detrusor function. Int J Clin Pharmacol Ther Toxicol. 1990;28(8):350-4.
Liu H, Liu P, Mao G, Chen G, Wang B, Qin X, et al. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. Urology. 2009;74(1):130-6.
Sussman DO. Overactive Bladder: Treatment Options in Primary Care Medicine. The Journal of the American Osteopathic Association. 2007;107(9):379-85.
Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs & aging. 2005;22(12):1013-28.
Luo D, Liu L, Han P, Wei Q, Shen H. Solifenacin for overactive bladder: a systematic review and meta-analysis. International urogynecology journal. 2012;23(8):983-91.
Medarov BI, Chaudhry H, Sun JH, Rane N, Judson MA. Effect of SSRIs and SNRIs on Nocturnal Urinary Frequency. The Annals of pharmacotherapy. 2016;50(6):471-4.
Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS spectrums. 2005;10(9):732-47.
Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU international. 2007;100(2):337-45.
Wang S-M, Lee H-K, Kweon Y-S, Lee CT, Lee K-U. Overactive Bladder Successfully Treated with Duloxetine in a Female Adolescent. Clin Psychopharmacol Neurosci. 2015;13(2):212-4.
Ghanbari Z, Esmaeili M, Eftekhar T, Esmaeili M, Miri E. COMPARISON OF EFFICACY AND SIDE-EFFECTS OF OXYBUTYNIN AND TOLTERODINE IN THE TREATMENT OF OVERACTIVE BLADDER. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ). 2011;69(5):302-8.
Basu M, Duckett JR. Detrusor overactivity successfully treated with duloxetine. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2007;27(4):438-40.
- Abstract Viewed: 147 times
- 6274/pdf Downloaded: 97 times